Catumaxomab: Difference between revisions
No edit summary |
No edit summary |
||
| Line 67: | Line 67: | ||
Catumaxomab consists of one "half" (one [[Immunoglobulin heavy chain|heavy chain]] and one [[Immunoglobulin light chain|light chain]]) of an anti-EpCAM antibody and one half of an anti-CD3 antibody, so that each molecule of catumaxomab can bind both EpCAM and CD3. In addition, the Fc-region can bind to an [[Fc receptor]] on accessory cells like other antibodies, which has led to calling the drug a [[trifunctional antibody]]. | Catumaxomab consists of one "half" (one [[Immunoglobulin heavy chain|heavy chain]] and one [[Immunoglobulin light chain|light chain]]) of an anti-EpCAM antibody and one half of an anti-CD3 antibody, so that each molecule of catumaxomab can bind both EpCAM and CD3. In addition, the Fc-region can bind to an [[Fc receptor]] on accessory cells like other antibodies, which has led to calling the drug a [[trifunctional antibody]]. | ||
[[File:Catumaxomab1.png|left|400px|This image is provided by the National Library of Medicine.]] | [[File:Catumaxomab1.png|left|400px|This image is provided by the National Library of Medicine.]] | ||
==Mechanism of action== | ==Mechanism of action== | ||
Many types of cancer cells carry EpCAM (epithelial cell adhesion molecule) on their surface. By binding to such a cell via one arm, to a [[T lymphocyte]] via the other arm and to an [[antigen-presenting cell]] like a [[macrophage]], a [[natural killer cell]] or a [[dendritic cell]] via the heavy chains, an immunological reaction against the cancer cell is triggered. Removing cancer cells from the abdominal cavity reduces the tumour burden which is seen as the cause for ascites in cancer patients.<ref name="EMEA">[http://www.emea.europa.eu/humandocs/PDFs/EPAR/removab/H-972-en6.pdf Assessment Report for Removab]</ref><ref>[http://www.fresenius.se/internet/fag/com/faginpub.nsf/Content/P-Info2004_01_15 Capital Market Day Fresenius Biotech: Fresenius concentrates biotechnology activities on antibody and innovative cell therapies]</ref><ref>{{Cite doi|10.1038.2Fsj.bjc.6603881}}</ref> | Many types of cancer cells carry EpCAM (epithelial cell adhesion molecule) on their surface. By binding to such a cell via one arm, to a [[T lymphocyte]] via the other arm and to an [[antigen-presenting cell]] like a [[macrophage]], a [[natural killer cell]] or a [[dendritic cell]] via the heavy chains, an immunological reaction against the cancer cell is triggered. Removing cancer cells from the abdominal cavity reduces the tumour burden which is seen as the cause for ascites in cancer patients.<ref name="EMEA">[http://www.emea.europa.eu/humandocs/PDFs/EPAR/removab/H-972-en6.pdf Assessment Report for Removab]</ref><ref>[http://www.fresenius.se/internet/fag/com/faginpub.nsf/Content/P-Info2004_01_15 Capital Market Day Fresenius Biotech: Fresenius concentrates biotechnology activities on antibody and innovative cell therapies]</ref><ref>{{Cite doi|10.1038.2Fsj.bjc.6603881}}</ref> | ||
[[File:Catumaxomab2.png|left|400px|This image is provided by the National Library of Medicine.]] | [[File:Catumaxomab2.png|left|400px|This image is provided by the National Library of Medicine.]] | ||
==References== | ==References== | ||
Revision as of 15:42, 8 April 2015
| Monoclonal antibody | |
|---|---|
| Type | Trifunctional antibody |
| Source | Template:Infobox drug/mab source |
| Target | EpCAM, CD3 |
| Clinical data | |
| Trade names | Removab |
| AHFS/Drugs.com | International Drug Names |
| [[Regulation of therapeutic goods |Template:Engvar data]] | |
| Routes of administration | intraperitoneal infusion |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
  (what is this?) (verify) | |
|
WikiDoc Resources for Catumaxomab |
|
Articles |
|---|
|
Most recent articles on Catumaxomab Most cited articles on Catumaxomab |
|
Media |
|
Powerpoint slides on Catumaxomab |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Catumaxomab at Clinical Trials.gov Clinical Trials on Catumaxomab at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Catumaxomab
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Catumaxomab Discussion groups on Catumaxomab Patient Handouts on Catumaxomab Directions to Hospitals Treating Catumaxomab Risk calculators and risk factors for Catumaxomab
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Catumaxomab |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Catumaxomab[1] (trade name Removab) is a rat-mouse hybrid monoclonal antibody which is used to treat malignant ascites, a condition occurring in patients with metastasizing cancer. It binds to antigens CD3 and EpCAM. It is in clinical trials in the United States currently and is used in Europe. It was developed by Fresenius Biotech and Trion Pharma (Germany).
History
Catumaxomab was developed by Trion Pharma, based on preliminary work by the Helmholtz Zentrum München. Fresenius Biotech conducted clinical trials and filed the drug for approval with the European Medicines Agency (EMA). It was approved in Europe on 20 April 2009.[2]
Indications
The drug is approved for the treatment of malignant ascites in patients with EpCAM-positive cancer if a standard therapy is not available.[3][4] Ascites is an accumulation of fluid in the peritoneal cavity.
Application
The usual treatment of malignant ascites is to puncture the peritoneum to let the accumulated fluid drain out. After the puncture, catumaxomab is given as an intraperitoneal infusion. The procedure is repeated four times within about eleven days. It has been shown that puncture free survival can be increased from 11 to 46 days with this treatment.[5]
Adverse effects
Common adverse effects include fever, nausea and vomiting. Fever and pain should be controlled by giving NSAIDs, analgetics or antipyretics before application of catumaxomab.[6] All side effects were fully reversible in studies. Most are caused by the liberation of cytokines.[7]
Chemical structure
Catumaxomab consists of one "half" (one heavy chain and one light chain) of an anti-EpCAM antibody and one half of an anti-CD3 antibody, so that each molecule of catumaxomab can bind both EpCAM and CD3. In addition, the Fc-region can bind to an Fc receptor on accessory cells like other antibodies, which has led to calling the drug a trifunctional antibody.
Mechanism of action
Many types of cancer cells carry EpCAM (epithelial cell adhesion molecule) on their surface. By binding to such a cell via one arm, to a T lymphocyte via the other arm and to an antigen-presenting cell like a macrophage, a natural killer cell or a dendritic cell via the heavy chains, an immunological reaction against the cancer cell is triggered. Removing cancer cells from the abdominal cavity reduces the tumour burden which is seen as the cause for ascites in cancer patients.[7][8][9]
References
- ↑ Linke, Rolf (2010). "Catumaxomab: Clinical development and future directions". mAbs. 2 (2): 129–136. doi:10.4161/mabs.2.2.11221. Unknown parameter
|coauthors=ignored (help) - ↑ TRION Pharma: Trifunctional Antibody Catumaxomab Kills Cancer Stem Cells
- ↑ European Public Assessment Report for Removab
- ↑ Heiss u.a.: The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer. (2010) 127: 2209-2221
- ↑ PMID 18694358 (PMID 18694358)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2009
- ↑ 7.0 7.1 Assessment Report for Removab
- ↑ Capital Market Day Fresenius Biotech: Fresenius concentrates biotechnology activities on antibody and innovative cell therapies
- ↑ Template:Cite doi
- Pages with script errors
- Pages with citations using unsupported parameters
- Pages with incomplete PMID references
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- Articles with changed CASNo identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drug has EMA link
- Drugboxes which contain changes to verified fields
- Infobox drug tracked parameters
- Drugs that are a monoclonal antibody
- Pages with broken file links
- Drug